MONTEREY, California, USA, April 28, 2026
BRC Therapeutics has announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application for BRC-002, enabling the company to advance into a Phase I clinical trial in healthy volunteers. This regulatory milestone represents a significant step forward in the development of a first-in-class cannabinoid-based therapeutic targeting Complex Regional Pain Syndrome (CRPS), a debilitating chronic pain condition with no approved treatments in the United States. The IND clearance underscores growing regulatory acceptance of botanical drug development pathways, particularly for therapies addressing high unmet medical needs in neurological and inflammatory diseases. With this approval, BRC Therapeutics moves closer to delivering a novel, multimodal treatment approach designed to improve both pain management and quality of life for patients suffering from CRPS.
Regulatory Milestone Accelerates Clinical Development Pathway
The IND clearance allows BRC Therapeutics to initiate a first-in-human Phase I study, primarily focused on evaluating the safety, tolerability, and pharmacokinetics of BRC-002. This milestone follows the therapy’s earlier Orphan Drug Designation, granted by the FDA, which recognizes its potential to address a rare condition affecting a limited patient population and provides incentives such as expedited development pathways and market exclusivity upon approval.
CRPS is a severe and often long-lasting condition characterized by intense chronic pain, inflammation, and neurological complications, frequently accompanied by depression, anxiety, and sleep disturbances. Current treatment options remain inadequate, often requiring long-term management without delivering meaningful functional relief. The FDA’s decision to clear the IND highlights confidence in BRC-002’s preclinical data and manufacturing readiness, reinforcing its potential as a transformative therapy in the pain management landscape.
Innovative Cannabinoid-Based Therapy Targets Unmet Needs
Advertisement
BRC-002 is a botanically derived, prescription-grade cannabinoid formulation composed of multiple cannabinoids in defined and proprietary ratios, designed to deliver a multimodal mechanism of action. Unlike traditional single-target drugs, this therapy aims to address the complex biological pathways underlying chronic pain and inflammation, offering a more holistic treatment approach. The therapy is engineered to modulate both neurological signaling and inflammatory responses, which are central to CRPS pathophysiology.
Given that there are currently no FDA-approved treatments for CRPS, the development of BRC-002 represents a potentially groundbreaking advancement in addressing a long-standing therapeutic gap. Furthermore, the program contributes to the broader evolution of cannabinoid-based pharmaceuticals, an emerging field that is gaining traction as scientific understanding and regulatory frameworks continue to evolve.
Advancing Botanical Drug Innovation Under cGxP Frameworks
The progression of BRC-002 into clinical development highlights the increasing importance of cGxP-compliant manufacturing, quality control, and regulatory validation in botanical drug development. Unlike conventional small-molecule drugs, cannabinoid-based therapies present unique challenges in standardization, consistency, and regulatory compliance, requiring rigorous Chemistry, Manufacturing, and Controls (CMC) processes. BRC Therapeutics has established cGMP-compliant production systems to ensure batch-to-batch consistency and meet stringent FDA requirements, positioning the company for efficient clinical progression and future commercialization.
This IND clearance not only advances BRC-002 but also signals broader industry momentum toward integrating plant-derived therapeutics into mainstream pharmaceutical pipelines. As clinical data emerges from upcoming trials, BRC-002 could redefine treatment strategies for chronic pain disorders and establish new benchmarks in botanical drug innovation, regulatory science, and patient-centric therapy development.
Source: BRC Therapeutics press release
